Top

Journal of Neuro-Oncology

Published in:

01-01-2019 | Laboratory Investigation

MiR-101-3p inhibits EMT to attenuate proliferation and metastasis in glioblastoma by targeting TRIM44

Authors: Ling Li, Mei-Ying Shao, Shu-Cheng Zou, Zhe-Feng Xiao, Zhu-Chu Chen

Published in: Journal of Neuro-Oncology | Issue 1/2019

Abstract

Background

Glioblastoma (GBM) is the most common malignant tumor originating in the brain parenchyma. The invasive and infiltrative properties of glioblastoma result in poor clinical prognosis to conventional therapies. Emerging reports on microRNAs as important regulators during the process of EMT provide new insights into treating glioblastoma through new targets. However, underlying molecular mechanism of the regulation of miR-101-3p in glioblastoma remains unclear.

Methods

Level of miR-101-3p was determined in GBM cell lines by qRT-PCR. MTT, colony formation and transwell assays were utilized to evaluate functions of overexpression of miR-101-3p/knock down of TRIM44 on proliferation, migration and invasion in GBM cells. Direct interaction between miR-101-3p and TRIM44 was validated using dual luciferase reporter system and impacts of overexpression of miR-101-3p/knock down of TRIM44 on regulation of EMT markers were assessed by Western blotting.

Results

MiR-101-3p was validated to be repressed expressed in glioblastoma cancer cell lines. Both overexpression of miR-101-3p and knock down of TRIM44 attenuated proliferation, migration and invasion of glioblastoma cell lines in vitro. TRIM44 was shown to promote EMT in GBM progress and reverse inhibitory function of miR-101-3p. MiR-101-3p was found to suppress the expression of TRIM44 via directly targeting its 3′UTR.

Conclusions

Our findings suggested miR-101-3p regulated proliferation and migration of glioblastoma cells through attenuating TRIM44 induced EMT via direct targeting 3′UTR of TRIM44, which provided preliminary study of potential therapeutic target in future GBM treatment.

Buckner JC et al (2007) Central nervous system tumors. Mayo Clin Proc 82(10):1271–1286CrossRefPubMed

Louis DN et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820CrossRefPubMed

Quick A et al (2010) Current therapeutic paradigms in glioblastoma. Rev Recent Clin Trials 5(1):14–27CrossRefPubMed

Iser IC et al (2017) The epithelial-to-mesenchymal transition-like process in glioblastoma: an updated systematic review and in silico investigation. Med Res Rev 37(2):271–313CrossRefPubMed

Mahabir R et al (2014) Sustained elevation of Snail promotes glial-mesenchymal transition after irradiation in malignant glioma. Neuro Oncol 16(5):671–685CrossRefPubMed

Liao H et al (2015) MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2. Oncotarget 6(11):8914–8928CrossRefPubMedPubMedCentral

Ying Xing QM, Chen X, Zhao Y, Liu W, Jing, Hu, Feng, Xue XW, Cai L (2016) TRIM44 promotes proliferation and metastasis in non-small cell. Oncotarget 7(21):30479–30491CrossRefPubMedPubMedCentral

Li Q et al (2016) MicroRNA-663 inhibits the proliferation, migration and invasion of glioblastoma cells via targeting TGF-beta1. Oncol Rep 35(2):1125–1134CrossRefPubMed

Chen W et al (2018) Downregulation of miR205 is associated with glioblastoma cell migration, invasion, and the epithelial-mesenchymal transition, by targeting ZEB1 via the Akt/mTOR signaling pathway. Int J Oncol 52(2):485–495PubMed

10.

Ma C et al (2017) MicroRNA-10b mediates TGF-beta1-regulated glioblastoma proliferation, migration and epithelial-mesenchymal transition. Int J Oncol 50(5):1739–1748CrossRefPubMed

11.

Yan Y et al (2015) miR-10a controls glioma migration and invasion through regulating epithelial-mesenchymal transition via EphA8. FEBS Lett 589(6):756–765CrossRefPubMed

12.

Smits M et al (2010) miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget 1(8):710–720CrossRefPubMed

13.

Xiaoping L et al (2013) CPEB1, a histone-modified hypomethylated gene, is regulated by miR-101 and involved in cell senescence in glioma. Cell Death Dis 4:e675CrossRefPubMedPubMedCentral

14.

Ma C et al (2016) miR-101 inhibits glioma cell invasion via the downregulation of COX-2. Oncol Lett 12(4):2538–2544CrossRefPubMedPubMedCentral

15.

Tian T et al (2016) MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3beta in glioblastoma. Oncotarget 7(48):79584–79595CrossRefPubMedPubMedCentral

16.

Liu N et al (2017) MicroRNA-101 inhibits proliferation, migration and invasion of human glioblastoma by targeting SOX9. Oncotarget 8(12):19244–19254CrossRefPubMed

17.

Hatakeyama S, Family Proteins TRIM (2017) Roles in autophagy, immunity, and carcinogenesis. Trends Biochem Sci 42(4):297–311CrossRefPubMed

18.

Hatakeyama S (2011) TRIM proteins and cancer. Nat Rev Cancer 11(11):792–804CrossRefPubMed

19.

Ong CA et al. (2014) Amplification of TRIM44: pairing a prognostic target with potential therapeutic strategy. J Natl Cancer Inst. https://doi.org/10.1093/jnci/dju050CrossRefPubMedPubMedCentral

20.

Kawabata H et al. (2017) TRIM44 is a poor prognostic factor for breast cancer patients as a modulator of NF-kappaB signaling. Int J Mol Sci 18(9):1931CrossRefPubMedPubMedCentral

21.

Xing Y et al (2016) TRIM44 promotes proliferation and metastasis in nonsmall cell lung cancer via mTOR signaling pathway. Oncotarget 7(21):30479–30491CrossRefPubMedPubMedCentral

22.

Zhou Z et al (2017) Knockdown of TRIM44 inhibits the proliferation and invasion in papillary thyroid cancer cells through suppressing the Wnt/beta-catenin signaling pathway. Biomed Pharmacother 96:98–103CrossRefPubMed

23.

Yamada Y et al (2017) A novel prognostic factor TRIM44 promotes cell proliferation and migration, and inhibits apoptosis in testicular germ cell tumor. Cancer Sci 108(1):32–41CrossRefPubMed

24.

Peng R et al. (2018) Elevated TRIM44 promotes intrahepatic cholangiocarcinoma progression by inducing cell EMT via MAPK signaling. Cancer Med 7:796–808CrossRef

25.

Ostrom QT et al (2014) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol 16(Suppl 4):iv1–i63CrossRefPubMedPubMedCentral

26.

Gui T, Shen K (2012) miRNA-101: a potential target for tumor therapy. Cancer Epidemiol 36(6):537–540CrossRefPubMed

27.

Zhao S et al (2015) Loss of microRNA-101 promotes epithelial to mesenchymal transition in hepatocytes. J Cell Physiol 230(11):2706–2717CrossRefPubMed

28.

Ye Z et al (2016) Downregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2. Oncotarget 7(25):37524–37535CrossRefPubMedPubMedCentral

29.

Guo F et al (2014) MiR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma. Oncol Rep 31(5):2021–2028CrossRefPubMedPubMedCentral

30.

Zheng M et al (2015) Snail and Slug collaborate on EMT and tumor metastasis through miR-101-mediated EZH2 axis in oral tongue squamous cell carcinoma. Oncotarget 6(9):6797–6810CrossRefPubMed

31.

Jiang W et al (2016) miRNA-101 suppresses epithelial-to-mesenchymal transition by targeting HMGA2 in pancreatic cancer cells. Anticancer Agents Med Chem 16(4):432–439CrossRefPubMed

32.

Chandra Mangalhara K et al (2017) ERK2-ZEB1-miR-101-1 axis contributes to epithelial-mesenchymal transition and cell migration in cancer. Cancer Lett 391:59–73CrossRefPubMed

33.

Cui Y et al (2017) Upregulated lncRNA SNHG1 contributes to progression of non-small cell lung cancer through inhibition of miR-101-3p and activation of Wnt/beta-catenin signaling pathway. Oncotarget 8(11):17785–17794CrossRefPubMedPubMedCentral

34.

Chen W et al (2017) MALAT1-miR-101-SOX9 feedback loop modulates the chemo-resistance of lung cancer cell to DDP via Wnt signaling pathway. Oncotarget 8(55):94317–94329CrossRefPubMedPubMedCentral

Title: MiR-101-3p inhibits EMT to attenuate proliferation and metastasis in glioblastoma by targeting TRIM44
Authors: Ling Li
Mei-Ying Shao
Shu-Cheng Zou
Zhe-Feng Xiao
Zhu-Chu Chen
Publication date: 01-01-2019
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 1/2019
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-018-2973-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

MiR-101-3p inhibits EMT to attenuate proliferation and metastasis in glioblastoma by targeting TRIM44

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

Brain T1ρ mapping for grading and IDH1 gene mutation detection of gliomas: a preliminary study

Survival of glioma patients in relation to mobile phone use in Denmark, Finland and Sweden

Eighty percent survival rate at 15 years for 1p/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade

Functional relevance of genes predicted to be affected by epigenetic alterations in atypical teratoid/rhabdoid tumors

Loss of programmed cell death 10 activates tumor cells and leads to temozolomide-resistance in glioblastoma

Comparative analysis of the diffusion kurtosis imaging and diffusion tensor imaging in grading gliomas, predicting tumour cell proliferation and IDH-1 gene mutation status